Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012)
Johnson & Johnson (JNJ) posted Income from Non-Controlling Interests of -$339.0 million for Q3 2012.
Johnson & Johnson (JNJ) Income from Non-Controlling Interests (2012) Analysis & Trends
Johnson & Johnson has reported Income from Non-Controlling Interests for 1 years, with the latest figure at -$339.0 million in Q3 2012.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$339.0 million in Q3 2012, while the trailing twelve-month figure through Dec 2013 was -$339.0 million (changed N/A YoY) and the FY2012 annual result came in at -$339.0 million, changed N/A from the prior year.
- Income from Non-Controlling Interests held at -$339.0 million in Q3 2012 per JNJ's latest filing.
- Over five years, Income from Non-Controlling Interests peaked at -$339.0 million in Q3 2012 and troughed at -$339.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 10.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 741.95 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 39.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | -339.00 Mn |